|Bid||29.50 x 1000|
|Ask||32.75 x 1300|
|Day's Range||30.50 - 31.65|
|52 Week Range||26.05 - 50.44|
|Beta (3Y Monthly)||1.14|
|PE Ratio (TTM)||102.81|
|Earnings Date||Feb 4, 2019 - Feb 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.00|
The study demonstrated patients who met existing National Comprehensive Cancer Network (NCCN) clinical testing criteria had similar rates of pathogenic/likely pathogenic hereditary mutations in breast cancer genes (9 percent) as patients who did not meet NCCN criteria (8 percent). “I am excited by our new ASBrS guidelines and look forward to the day when NCCN updates its guidelines also.
SALT LAKE CITY, Feb. 13, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at.
NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
SALT LAKE CITY, Feb. 11, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that its Myriad Women’s Health subsidiary has.
Myriad Genetics Inc NASDAQ/NGS:MYGNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for MYGN with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding MYGN totaled $1.33 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Myriad Genetics, Inc. (MYGN), a global leader in molecular diagnostics and personalized medicine, today announced that its Myriad Women’s Health business unit will present new data from eight studies at the 2019 Society for Maternal-Fetal Medicine (SMFM) being held Feb. 11-16, 2019 in Las Vegas, NV. Please visit Myriad Women’s Health at booth 401 to learn more about our leading portfolio of women’s health products. Follow Myriad on Twitter via @myriadgenetics and keep up to date with meeting news and updates by using the hashtag #SMFM19.
Myriad Genetics (MYGN) Q2 performance by Hereditary Cancer testing is encouraging while GeneSight test revenues disappoint.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 5) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Array ...
The Salt Lake City-based company said it had net income of 3 cents per share. Earnings, adjusted for one-time gains and costs, were 38 cents per share. The results did not meet Wall Street expectations. ...
Total Second-Quarter Revenues of $216.8 Million, Up 15 PercentSecond-Quarter Diluted EPS of $0.03 and Adjusted EPS of $0.38, Up 6 Percent SALT LAKE CITY, Feb..
NEW YORK, NY / ACCESSWIRE / February 5, 2019 / Myriad Genetics, Inc. (NASDAQ: MYGN ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on February 6, 2019 at 4:30 ...
Myriad (MYGN) likely to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SALT LAKE CITY, Jan. 28, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will hold its fiscal.
On the success of the Elevate 2020 program, along with augmenting reimbursements for tests, Myriad Genetics (MYGN) seems to be well-positioned to deliver strong financial results in fiscal 2019.
Epizyme (EPZM) announces that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma.